Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic and Prognostic Role of New Inflammation Biomarkers in Patients With Malignant Pleural Mesothelioma

NCT02300883 is registered in ClinicalTrials.gov with Armando Santoro, MD as lead sponsor.

NCT NCT02300883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02300883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic and Prognostic Role of New Inflammation Biomarkers in Patients With Malignant Pleural Mesothelioma
Lead sponsor
Armando Santoro, MD
Phase
Observational
Overall status
Completed
Start date
April 30, 2011
Completion date
January 31, 2018
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant mesothelioma